Tempest Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated August 15, 2022, reports the financial results for Tempest Therapeutics, Inc. for the second fiscal quarter ended June 30, 2022. The Company is a biopharmaceutical entity focused on developing novel therapeutics, with its principal executive offices located in South San Francisco, CA.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document serves as a notification that a press release containing these details (Exhibit 99.1) has been issued, but the specific financial data points are not embedded within the text of this 8-K form.
Material Changes
No material changes or comparative financial data versus the prior period are detailed in the provided text. The filing references an attached press release for corporate highlights and operational results.
Guidance, Outlook, and Risks
The filing does not contain specific guidance, outlook, management commentary, or risk factors within the body of the text. It explicitly states that the information is furnished under Item 2.02 and is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor incorporated by reference into other filings except as expressly set forth.
Investor Verification Checklist
- Review the attached Exhibit 99.1 (Press Release dated August 15, 2022) for specific Q2 2022 financial figures.
- Verify the Company's cash position and runway given the lack of revenue disclosure in this summary.
- Confirm the status of clinical trials and corporate highlights mentioned in the referenced press release.
- Check for any subsequent filings that may incorporate the press release by reference.